Exhibit 99


                   EXHIBIT 99 TO THE ANNUAL REPORT FORM 10-K
                  FOR THE FISCAL YEAR ENDED DECEMBER 31, 1995

           CAUTIONARY STATEMENTS REGARDING "SAFE HARBOR" PROVISIONS
            OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

      The Company's 1995 Annual Report to Shareholders and Form 10-K are among
certain communications by the Company which contain forward looking statements
including statements regarding its financial position, results of operations,
market position and product development. These forward looking statements are
based on current expectations. As permitted by the Private Securities
Litigation Reform Act of 1995, the Company is hereby filing the following
cautionary statements identifying important factors which, among others, could
cause the Company's actual results to differ materially from expected and
historical results. 

      Changing business conditions including inflation and fluctuations in
      interest rates and foreign currency exchange rates. 

      Competitive factors including managed care groups, institutions and
      government agencies seeking price discounts; technological advances
      attained by competitors; patents granted to competitors; and generic
      competition as the Company's products mature. 

      Government laws and regulations affecting domestic and international
      operations, including trade, monetary and fiscal policies, taxes, price
      controls, unstable governments and legal systems and intergovernmental
      disputes, possible nationalization, as well as actions affecting
      approvals of products and licensing. 

      Adverse publicity and developments resulting from questions raised from
      the use of calcium channel blockers. 

      Changes in the current tax law such as those currently being considered
      by the U.S. Congress and the Clinton Administration which would amend
      the Section 936 income tax credit so as to completely phase out the
      income-based tax credit for those companies with operations in Puerto
      Rico, where the Company has a major manufacturing facility. Both
      proposals provide for the phase down of the Section 936 credit over a
      period of five to ten years. 

      Difficulties or delays in product development including, but not limited
      to, the inability to identify viable new chemical compounds,
      successfully complete clinical trials, obtain regulatory approval for
      the compounds or gain market acceptance of approved products. Similar
      difficulties or delays can also affect the development of the Company's
      other businesses. 

      Growth in costs and expenses including changes in product mix and the
      impact of divestitures, restructuring and other unusual items that could
      result from evolving business strategies, evaluation of asset
      realization, and organizational structures. 

      Issuance of unfavorable accounting standards and rules. 

      Changing social conditions. 

      Significant litigation adverse to the Company. 

      Business combinations among the Company's competitors could affect the
      Company's ranking in the pharmaceutical industry.